Equities

CNBX Pharmaceuticals Inc

CNBX:PKC

CNBX Pharmaceuticals Inc

Actions
  • Price (USD)0.0102
  • Today's Change0.00 / 0.00%
  • Shares traded162.00
  • 1 Year change-15.00%
  • Beta0.8554
Data delayed at least 15 minutes, as of Nov 25 2024 20:45 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Aug 31 2023202320222021
ASSETS
Cash And Short Term Investments0.130.121.39
Total Receivables, Net------
Total Inventory------
Prepaid expenses0.090.080.20
Other current assets, total------
Total current assets0.220.201.59
Property, plant & equipment, net0.270.440.64
Goodwill, net------
Intangibles, net------
Long term investments00.180.85
Note receivable - long term------
Other long term assets------
Total assets0.500.813.08
LIABILITIES
Accounts payable------
Accrued expenses------
Notes payable/short-term debt1.341.760.87
Current portion long-term debt/capital leases------
Other current liabilities, total0.840.220.22
Total current liabilities2.522.441.27
Total long term debt000
Total debt1.341.760.87
Deferred income tax------
Minority interest------
Other liabilities, total--0--
Total liabilities2.522.441.27
SHAREHOLDERS EQUITY
Common stock0.000.000.01
Additional paid-in capital221817
Retained earnings (accumulated deficit)(24)(21)(17)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total00.881.55
Total equity(2.02)(1.63)1.81
Total liabilities & shareholders' equity0.500.813.08
Total common shares outstanding231.261.24
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.